Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study

被引:8
|
作者
Xiao, Zhijian [1 ,2 ,3 ,4 ]
Xu, Zefeng [1 ,2 ,3 ]
Zhang, Yue [1 ,2 ,3 ]
Qin, Tiejun [1 ,2 ,3 ]
Zhang, Hongli [1 ,2 ,3 ]
Fang, Liwei [1 ,2 ,3 ]
机构
[1] Chinese Acad Med Sci, Inst Hematol, Dept Clin Hematol 6, Tianjin 300020, Peoples R China
[2] Blood Dis Hosp, Chinese Acad Med Sci, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China
关键词
Myelodysplastic syndromes; Treatment; Cyclosporin A; Thalidomide; LOW-RISK; ANTITHYMOCYTE GLOBULIN; PHASE-II; IMMUNOSUPPRESSIVE THERAPY; LENALIDOMIDE; PREDICTS;
D O I
10.1016/j.leukres.2010.06.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We reported 37 patients with myelodysplastic syndromes (MDS) of refractory cytopenia with multilineage dysplasia or refractory anemia with excess blasts who were treated with cyclosporin A (CyA)/thalidomide combination therapy. Of them, 19 patients (19/37, 51.4%) achieved a hematologic improvement and erythroid response (HI-E); 9 patients (9/29, 31.0%) achieved hematologic improvement and platelet response (HI-P) and 7 patients (7/33, 21.2%) achieved hematologic improvement and neutrophil response (HI-N). 15 of 32 (46.9%) transfusion-dependent patients achieved independence from transfusion. The median response duration of HI-E, HI-P and HI-N were 88 (4-108) weeks, 78 (8-84+) weeks and 78(10-84+) weeks, respectively. Some patients presented with I or II grade hepatic or nephritic impairment, constipation, lethargy, dizziness, edema, rash or sense of numbness. Therefore, CyA combined with thalidomide appears to be useful and is relatively well-tolerated for patients with MDS. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:61 / 65
页数:5
相关论文
共 50 条
  • [1] Thalidomide for the treatment of patients with myelodysplastic syndromes
    Strupp, C
    Germing, U
    Aivado, M
    Misgeld, E
    Haas, R
    Gattermann, N
    [J]. LEUKEMIA, 2002, 16 (01) : 1 - 6
  • [2] Thalidomide for the treatment of patients with myelodysplastic syndromes
    C Strupp
    U Germing
    M Aivado
    E Misgeld
    R Haas
    N Gattermann
    [J]. Leukemia, 2002, 16 : 1 - 6
  • [3] A pilot study of treatment with mesterlone, prednisone and low-dose thalidomide for patients with Myelodysplastic syndromes.
    Aguayo, Alvaro
    Garcia-Alvarez, Eunice
    Crespo-Solis, Erick
    Martinez-Banos, Deborah
    Lopez-Karpovitch, Xavier
    [J]. BLOOD, 2007, 110 (11) : 221B - 221B
  • [4] Thalidomide in myelodysplastic syndromes
    Zorat, F
    Pozzato, G
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (01) : 20 - 30
  • [5] The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes
    Zorat, F
    Shetty, V
    Dutt, D
    Lisak, L
    Nascimben, F
    Allampallam, K
    Dar, S
    York, A
    Gezer, S
    Venugopal, P
    Raza, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) : 881 - 894
  • [6] Delayed responses to thalidomide in patients with myelodysplastic syndromes.
    Lisak, LA
    Little, L
    Dean, L
    Ekbal, M
    duRandt, M
    Hussain, M
    Kaistha, V
    Raza, A
    [J]. BLOOD, 2000, 96 (11) : 261B - 261B
  • [7] ALL-TRANS-RETINOIC ACID IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - RESULTS OF A PILOT-STUDY
    AUL, C
    RUNDE, V
    GATTERMANN, N
    [J]. BLOOD, 1993, 82 (10) : 2967 - 2974
  • [8] A phase II pilot study of sorafenib in patients with myelodysplastic syndromes
    de Castro, C.
    Adams, D.
    Rizzieri, D.
    Moore, J.
    Gockerman, J.
    Diehl, L.
    Horwitz, M.
    Edmonds, E.
    Warzecho, J.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S137 - S137
  • [9] Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders
    Thomas, DA
    [J]. SEMINARS IN HEMATOLOGY, 2000, 37 (01) : 26 - 34
  • [10] Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS).
    Raza, A
    Dutt, D
    Lisak, L
    Dean, L
    Fantroy, L
    Gezer, S
    Syed, E
    Goldberg, C
    Loew, J
    Hsu, WT
    Venugopal, P
    [J]. BLOOD, 2001, 98 (11) : 273B - 274B